Feature

In the battle to control drug costs, old patent laws get new life


 

KHN’s coverage of prescription drug development, costs, and pricing is supported in part by the Laura and John Arnold Foundation. Kaiser Health News is a nonprofit national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation that is not affiliated with Kaiser Permanente.

Pages

Recommended Reading

Medicare gets input on revamping Part B drug program
MDedge Internal Medicine
Is CMS becoming more open to PTAC recommendations?
MDedge Internal Medicine
Proposal to change Part B drug WAC-based reimbursement draws criticism
MDedge Internal Medicine
5 things to know about Trump’s new ‘public charge’ immigration proposal
MDedge Internal Medicine
House, Senate agree on broad opioid legislation
MDedge Internal Medicine
Does America have a gabapentinoid problem?
MDedge Internal Medicine
Transgender equality: U.S. physicians must lead the way
MDedge Internal Medicine
Physical assaults in the emergency department on the rise, survey finds
MDedge Internal Medicine
The patient who doesn’t like you
MDedge Internal Medicine
Employer health insurance: Deductibles rising faster than wages
MDedge Internal Medicine